| http://www.w3.org/ns/prov#value | - Also excluded were studies that involved lower extremity spasticity only, used botulinum toxin (BTX) formulations not commercially available in USA, focused on treatments for spasticity secondary to diseases other than stroke or included a majority of patients whose spasticity was not secondary to stroke.
|
